Mark V. Mishra

Mark V. Mishra, MD, is a Professor in the Department of Radiation Oncology at the University of Maryland School of Medicine. He specializes in treating central nervous system tumors, genitourinary cancers, and breast cancer. Dr. Mishra holds significant administrative roles, including Associate Director for Cancer Networks, Vice Chair for Clinical Research, and Director of Radiation Oncology Clinical Research. He leads clinical trials across Maryland and serves as UMGCCC's Voting-Member Contact PI for NRG Oncology.

Education:

• MD: University of Cincinnati College of Medicine
• Residency: Radiation Oncology, Thomas Jefferson University (Chief Resident)
• Fellowship: NIH Clinical Research Training Program
• Certificate: Program in Clinical Effectiveness, Harvard T.H. Chan School of Public Health

Research Focus: Dr. Mishra's work centers on comparative/cost-effectiveness of radiation technologies (e.g., proton therapy) and novel radiation combinations. He leads national phase III trials for brain metastases (NRG BN009/CC009) and investigator-initiated studies combining laser interstitial thermal therapy with radiation for gliomas. His research integrates health economics, patient-centered outcomes, and therapeutic innovation.

Publications: With 75+ peer-reviewed publications (1,100+ citations), his work spans neuro-oncology, prostate cancer, health economics, and treatment optimization. Recent articles emphasize systematic reviews of radiation economics, patient preference analysis, and survival modeling for pancreatic/glioma cancers.

Honors & Grants:

• ASTRO Comparative Effectiveness Grant
• NCI Cancer Center Investigator Team Leadership Award
• Baltimore Magazine 'Top Doctor'
• Funding from NIH, PCORI, ASTRO, and Keep Punching Foundation

Leadership: Dr. Mishra chairs the Radiation Oncology Executive Academic and Advisory Council, serves on ASTRO/ACR committees, and contributes to the PCORI Patient Engagement Advisory Panel. He oversees clinical trial networks enhancing statewide cancer care access.